MedTrace Logo

A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy

NCT03003884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2017-09-08

No results posted yet for this study

Summary

The purpose of this study is to find out the optimal dose for Remimazolam Tosilate as a procedural sedative during a diagnostic upper GI endoscopy and to assess its efficacy and safety profile comparing to propofol.

Conditions

  • Sedation

Interventions

DRUG

Remimazolam Tosilate

Initial dose plus supplemental doses as necessary.

DRUG

Propofol

Initial dose plus supplemental doses as necessary.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03003884 on ClinicalTrials.gov